BioSpace News Archive

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at the EORTC-NCI-AACR (“ENA”) annual meeting to be held October 26-28, 2022.

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, announced the publication of the 24-month analysis from the BRAVO Study in Annals of Medicine and Surgery.

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2022 on Wednesday, Nov. 2 at 9 a.m., ET.

Cigna Corporation, a global health service company, unveiled new insights from the Evernorth Vitality IndexTM, the largest study on the state of vitality, health and productivity in America.

ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX) today announced the presentation of updated clinical data from the first two cohorts of the Phase 1/2 study of ESSA’s lead candidate EPI-7386 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (“mCRPC”).

Pleno Inc., a multi-omic instrument platform company revolutionizing biological target detection for clinical testing and biomedical research, announced that Jason Trachewsky has joined the company as Vice President of Software, and Professor Nambi Seshadri, Ph.D. has joined as Chairman of Pleno’s Scientific Advisory Board.

Expansion Therapeutics, Inc. today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso, President and Chief Executive Officer of Precision BioSciences (the “Company”) under the Company’s 2021 Employment Inducement Incentive Award Plan.

Alterity Therapeutics today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy natural history study was given at the 147th Annual Meeting of the American Neurological Association (ANA) on October 24, 2022.

Ikena Oncology, Inc. today announced a poster presentation highlighting preclinical data on the company’s novel TEAD inhibitor, IK-930, at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 26-28, 2022, in Barcelona, Spain.